Fungal infections in leukemia patients: How do we prevent and treat them?

Clinical Infectious Diseases

Volumn 50, Issue 3, 2010, Pages 405-415

  Leventakos, Konstantinos ^a   Lewis, Russell E ^a,b   Kontoyiannis, Dimitrios P ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; BETA 1,3 GLUCAN; BETA LACTAM ANTIBIOTIC; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FUNGAL DNA; GALACTOMANNAN; GLUCOCORTICOID; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; PROTON PUMP INHIBITOR; PYRROLE; PYRROLE DERIVATIVE; TACROLIMUS; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ASPERGILLOSIS; ASPERGILLUS; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CANDIDA; CANDIDIASIS; COMPUTER ASSISTED TOMOGRAPHY; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; INFECTION RISK; LEUKEMIA; MEDICAL DECISION MAKING; MEDICAL DOCUMENTATION; MUCORMYCOSIS; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NONHUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SAPROTROPH; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; CHEMOPREVENTION; HUMANS; IMMUNOCOMPROMISED HOST; LEUKEMIA; MYCOSES;

EID: 75749148763     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/649879     Document Type: Review

References (105)

1. Kontoyiannis DP. Why prior fluconazole use is associated with an increased risk of invasive mold infections in immunosuppressed hosts: an alternative hypothesis. Clin Infect Dis 2002; 34(9):1281-1283.
2. 2. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37(9):1172-1177. (Pubitemid 37372504)
3. 3. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34(7):909-917. (Pubitemid 34229758)
4. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91(7):986-989.
5. Marr KA. The changing spectrum of candidemia in oncology patients: therapeutic implications. Curr Opin Infect Dis 2000; 13(6):615-620.
6. 6. Pagano L, Antinori A, Ammassari A, et al. Retrospective study of candidemia in patients with hematological malignancies: clinical features, risk factors and outcome of 76 episodes. Eur J Haematol 1999; 63(2):77-85. (Pubitemid 29399619)
7. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48(12):1695-1703.
8. Lin MY, Carmeli Y, Zumsteg J, et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother 2005; 49(11):4555-4560.
9. Sipsas NV, Lewis RE, Tarrand J, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009; 115(20):4745-4752.
10. 10. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM2004 study. Haematologica 2006; 91(8):1068-1075. (Pubitemid 44208634)
11. Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis 2002; 21(3):161-172.
12. 12. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32(3):358-366. (Pubitemid 32173620)
13. Steinbach WJ, Benjamin DK Jr, Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39(2):192-198.
14. 14. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005; 41(1):60-66. (Pubitemid 40863745)
15. Nucci M, Marr KA. Emerging fungal diseases. Clin Infect. Dis 2005; 41(4):521-526.
16. Wingard JR. Learning from our failures: the antifungal treatment conundrum. Clin Infect. Dis 2008; 46(9):1434-1435.
17. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48(3):265-273.
18. Slobbe L, Polinder S, Doorduijn JK, et al. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin Infect Dis 2008; 47(12):1507-1512.
19. Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis 2002; 21(3):161-172.
20. 20. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46(3):327-360. (Pubitemid 351265310)
21. 21. Tarrand JJ, Lichterfeld M, Warraich I, et al. Diagnosis of invasive septate mold infections-a correlation of microbiological culture and histologic or cytologic examination. Am J Clin Pathol 2003; 119(6): 854-858. (Pubitemid 37047847)
22. 22. Lass-Florl C, Resch G, Nachbaur D, et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007; 45(7):e101-e104. (Pubitemid 47580399)
23. 23. Torres HA, Rivero GA, Lewis RE, Hachem R, Raad II, Kontoyiannis DP. Aspergillosis caused by nonfumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus. Diagn Microbiol Infect Dis 2003; 46(1):25-28. (Pubitemid 36556017)
24. Hayden RT, Isotalo PA, Parrett T, et al. In situ hybridization, for the differentiation of Aspergillus, Fusarium, and Pseudallescheria species in tissue section. Diagn Mol Pathol 2003; 12(1):21-26.
25. 25. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97(6):1604-1610. (Pubitemid 32217224)
26. 26. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4(6):349-357. (Pubitemid 38692699)
27. Marr KA, Laverdiere M., Gugel A, Leisenring W Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40(12):1762-1769.
28. 28. Marr KA, Balajee SA, McLaughlin L, Tabouret. M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190(3):641-649. (Pubitemid 38982107)
29. Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, Ostrosky-Zeichner L. In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob Agents Chemother 2004; 48(5): 1912-1915.
30. 30. Pickering JW, Sant HW, Bowles CA, Roberts WL, Woods GL. Evaluation of a (l->3)-β-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005; 43(12):5957-5962. (Pubitemid 43100644)
31. Marty FM, Lowry CM, Lempitski SJ, Kubiak DW, Finkelman MA, Baden LR. Reactivity of ( l->3)-β-d-glucan assay with commonly used intravenous antimicrobials. Antimicrob Agents Chemother 2006; 50(10):3450-3453.
32. Mennink-Kersten MA, Ruegebrink D, Verweij PE. Pseudomonas aeruginosa as a cause of 1,3-β-D-glucan assay reactivity. Clin Infect Dis 2008; 46(12):1930-1931.
33. Lass-Florl C, Aigner J, Gunsilius E, et al. Screening for Aspergillus spp using polymerase chain reaction of whole blood samples from patients with haematological malignancies. Br J Haematol 2001; 113(1):180-184.
34. Donnelly JP. Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go. Clin Infect Dis 2006; 42(4):487-489.
35. 35. Pazos C, Ponton J, Del Palacio A. Contribution of (1->3)-β-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005; 43(1):299-305. (Pubitemid 40096315)
36. Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47(5):674-683.
37. 37. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19(1):253-259. (Pubitemid 32063503)
38. Caillot D, Mannone L, Cuisenier B, Couaillier JF. Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients. Clin Microbiol Infect 2001; 7:54-61.
39. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44(3):373-379.
40. Verweij PE, van Die L, Donnelly JP. Halo sign and improved outcome. Clin Infect Dis 2007; 44(12):1666-1667.
41. 41. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15(1):139-147. (Pubitemid 27020567)
42. 42. Wahba H, Truong MT, Lei X, Kontoyiannis DP, Marom EM. Reversed halo sign in invasive pulmonary fungal infections. Clin Infect Dis 2008; 46(11):1733-1737. (Pubitemid 351706772)
43. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49 (9):3640-3645.
44. Garey KW, Neuhauser MM, Bearden DT, et al. Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study. Mycoses 2006; 49(3):226-231.
45. von Eiff M, Roos N, Schulten R, Hesse M, Zuhlsdorf M, van de Loo J. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 1995; 62:341-347.
46. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47(4):503-509.
47. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26:1383-1396.
48. Cagnoni PJ, Walsh TJ, Prendergast MM, et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000; 18(12):2476-2483.
49. 49. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998; 27: 603-618. (Pubitemid 28422013)
50. Groll AH, Lyman CA, Petraitis V, et al. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob Agents Chemother 2006; 50(10):3418-3423.
51. 51. Lewis RE, Liao G, Hou J, Chamilos G, Prince RA, Kontoyiannis DP. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2007; 51(4):1253-1258. (Pubitemid 46586802)
52. Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000; 182(1):274-282.
53. Bruggemann RJ, Touw DJ, Aarnoutse RE, Verweij PE, Burger DM. International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. Antimicrob Agents Chemother 2009; 53(1):303-305.
54. 54. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004; 57(2):218-222. (Pubitemid 38223535)
55. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009; 53(1):24-34.
56. 56. Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect, of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004; 21(5): 645-653. (Pubitemid 38447146)
57. 57. Green LJ, Marder P, Mann LL, Chio LC, Current. WL. LY303366 exhibits rapid and potent fungicidal activity in flow cytometric assays of yeast viability. Antimicrob Agents Chemother 1999; 43(4):830-835. (Pubitemid 29165745)
58. Wheeler RT, Fink GR. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog 2006; 2(4):e35.
59. Hohl TM, Feldmesser M., Perlin DS, Pamer EG. Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stagespecific effects on fungal β-glucan exposure. J Infect Dis 2008; 198(2): 176-185.
60. 60. Lamaris GA, Lewis RE, Chamilos G, et al. Caspofungin-mediated βglucan unmasking and enhancement of human polymorphonuclear neutrophil activity against. Aspergillus and non-Aspergillus hyphae. J Infect Dis 2008; 198(2):186-192. (Pubitemid 352019283)
61. Denning DW Echinocandin antifungal drugs. Lancet. 2003; 362(9390): 1142-1151.
62. 62. Marr KA. Fungal infections in hematopoietic stem cell transplant recipients. Med Mycol 2008; 46(4):293-302. (Pubitemid 351552484)
63. 63. Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008; 46(9):1401-1408. (Pubitemid 351589940)
64. 64. Comely OA, Maertens J, Winston DJ, et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356(4):348-359. (Pubitemid 46148777)
65. Wingard J, Carter S, Walsh T, et al. Results of a randomized, doubleblind trial of fluconazole (FLU) vs voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients. Blood 2007; 110(11):abstract 163.
66. Siwek GT, Pfaller MA, Polgreen PM, et al. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn Microbiol Infect Dis 2006; 55(3):209-212.
67. Sipsas NV, Kontoyiannis DP. Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies. Clin Infect Dis 2006; 42(11):1584-1591.
68. Stam WB, O'Sullivan AK, Rijnders B, et al. Economic evaluation of posaconazole vs standard azole prophylaxis in high-risk neutropenic patients in the Netherlands. Eur J Haematol 2008; 81(6):467-474.
69. 69. Eckmanns T, Ruden H, Gastmeier P. The influence of high-efficiency particulate air filtration on mortality and fungal infection among highly immunosuppressed patients: a systematic review. J Infect Dis 2006; 193(10):1408-1418. (Pubitemid 43673389)
70. Centers for Disease Control and Prevention; Infectious Diseases Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients [published correction appears in MMWR Recomm Rep 2004; 53(19):396].
71. MMWR Reconnu Rep 2000; 49(RR-10):1-125, CE1-7.
72. Wards A, Klaassen CHW, Meis J, et al. Molecular epidemiology of Aspergillus fumigatus isolates recovered from water, air, and patients shows two clusters of genetically distinct strains. J Clin Microbiol 2003; 41(9):4101-4106.
73. Gardner A, Mattiuzzi G, Faderl S, et al. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol 2008; 26(35):5684-5688.
74. 73. Sipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer 2005; 103(6):1103-1113. (Pubitemid 40328079)
75. 74. Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004; 10:48-66. (Pubitemid 38379951)
76. 75. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340:764-771. (Pubitemid 29114295)
77. Walsh TJ, Arndt C, Dismukes W. Liposomal amphotericin B for fever and neutropenia-reply. N Engl J Med 1999; 341(15):1154-1155.
78. 77. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346(4): 225-234. (Pubitemid 34438861)
79. 78. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41(9):1242-1250. (Pubitemid 41534660)
80. Maertens J, Glasmacher A, Selleslag D, et al. Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study. Clin Infect Dis 2005; 41 (1):e9-e14.
81. Hebart H, Loffler J, Reitze H, et al. Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: implications for the management of febrile neutropenia. Br J Haematol 2000; 111(2):635-640.
82. Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009; 48(8):1042-1051.
83. Pappas PG, Kauftman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48(5):503-535.
84. Kontoyiannis D. Echinocandin-based initial therapy in fungemic patients with cancer: a focus on recent guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009; 49(4):638-639.
85. 84. Comely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44(10):1289-1297. (Pubitemid 46717290)
86. 85. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347(6):408-415. (Pubitemid 34851833)
87. Kontoyiannis DP, Lewis RE. Toward more effective antifungal therapy: the prospects of combination therapy. Br J Haematol 2004; 126(2): 165-175.
88. 87. Yeghen T, Kibbler CC, Prentice HG, et al. Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution. Clin Infect Dis 2000; 31(4): 859-868. (Pubitemid 32299339)
89. van Burik JA, Hare RS, Solomon. HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42(7):e61-e65.
90. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50(1): 126-133.
91. 90. Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008; 47(3):364-371. (Pubitemid 352009357)
92. 91. Ibrahim AS, Gebermariam T, Fu Y, et al. The iron, chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007; 117(9):2649-2657. (Pubitemid 47494365)
93. 92. Reed C, Ibrahim A, Edwards JE Jr, Walot I, Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 2006; 50(11):3968-3969. (Pubitemid 44684931)
94. 93. John BV, Chamilos G, Kontoyiannis DP. Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin Microbiol Infect 2005; 11(7):515-517. (Pubitemid 40895150)
95. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for lesscommon, emerging, or refractory fungal infections. Clin Infect. Dis 2003; 36(9):1122-1131.
96. Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42(10): 1398-1403.
97. 96. Kelleher P, Goodsall A, Mulgirigama A, et al. Interferon-γ therapy in two patients with progressive chronic pulmonary aspergillosis. Eur Respir J 2006; 27(6):1307-1310. (Pubitemid 44914315)
98. 97. Safdar A. Antifungal immunity and adjuvant cytokine immune enhancement in cancer patients with invasive fungal infections. Clin Microbiol Infect 2007; 13(1):1-4. (Pubitemid 44869201)
99. 98. Safdar A, Rodriguez GH, Lichtiger B, et al. Recombinant interferonγ 1b immune enhancement, in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer 2006; 106(12):2664-2671. (Pubitemid 43911836)
100. Rowe JM, Rubin A, Mazza JJ, et al. Incidence of infections in adult patients (>55 years) with acute myeloid leukemia treated with yeastderived GM-CSF (Sargramostim): results of a double-blind prospective study by the Eastern Cooperative Oncology Group. In: Hiddemann W, Büchner T, Wörman B, eds. Acute leukemias V: experimental approaches and management of refractory diseases. Berlin: Springer-Verlag, 1996:178-184.
101. 100. Mousset S, Hermann S, Klein SA, et al. Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol 2005; 84(11):734-741. (Pubitemid 41447808)
102. Shaneyfelt TM, Centor RM. Reassessment of clinical practice guidelines: go gently into that good night. JAMA 2009; 301(8):868-869.
103. Tsimberidou AM, Estey E. Relevance of clinical trials in acute myeloid leukaemia. Hematol Oncol 2008; 26(3):182-183.
104. 103. Kontoyiannis DP, Chamilos G, Lewis RE, et al. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 2007; 110(6):1303-1306. (Pubitemid 47435602)
105. 104. Weiser MA, Cabanillas ME, Konopleva M, et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer 2004; 100(6):1179-1185. (Pubitemid 38325945)